| 2024-09-20 |
[News] Families of cancer victims wait for benefits decades after the World Trade Center attack |
Karl Gruber |
|
| 2024-09-20 |
[News] ESMO Congress 2024 |
Cheryl Lai |
|
| 2024-09-15 |
[Articles] Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study |
Arun A Azad, Mathias Bressel, Hsiang Tan, Mark Voskoboynik, Aneta Suder, Andrew J Weickhardt, Alexander Guminski, Roslyn J Francis, Javad Saghebi, Nattakorn Dhiantravan, Anthony M Joshua, Louise Emmett, Lisa Horvath, Declan G Murphy, Edward Hsiao, Bavanth |
|
| 2024-09-14 |
[Articles] Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study |
Othon Iliopoulos, Ane B Iversen, Vivek Narayan, Benjamin L Maughan, Kathryn E Beckermann, Stephane Oudard, Tobias Else, Jodi K Maranchie, Cynthia Muller Goldberg, Wei Fu, Rodolfo F Perini, Yanfang Liu, W Marston Linehan, Ramaprasad Srinivasan, Eric Jonasc |
|
| 2024-09-13 |
[News] Petition to end travel insurance discrimination against people with cancer |
Manjulika Das |
|
| 2024-09-13 |
[News] Rising costs of cancer medicines |
Sharmila Devi |
|
| 2024-09-12 |
[Articles] Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial |
Zikun Peng, Huayi Li, Yunong Gao, Li Sun, Jie Jiang, Bairong Xia, Yi Huang, Yu Zhang, Yu Xia, Yuxin Zhang, Yiyang Shen, Bowen Huang, Jiayu Nie, Xinrong Chen, Xingyu Liu, Cui Feng, Zhen Li, Wei Zhang, Kangjia Tao, Qiuxue Zhang, Shican Duan, Yaheng Chen, Ye |
|
| 2024-09-11 |
[Articles] Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial |
Alessandra Tedeschi, Anna Maria Frustaci, Adalgisa Condoluci, Marta Coscia, Roberto Chiarle, Pier Luigi Zinzani, Marina Motta, Gianluca Gaidano, Giulia Quaresmini, Lydia Scarfò, Gioacchino Catania, Marina Deodato, Rebecca Jones, Valentina Tabanelli, Valen |
|
| 2024-09-11 |
[Articles] [89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial |
Brian Shuch, Allan J Pantuck, Jean-Christophe Bernhard, Michael A Morris, Viraj Master, Andrew M Scott, Charles van Praet, Clement Bailly, Bülent Önal, Tamer Aksoy, Robin Merkx, David M Schuster, Sze Ting Lee, Neeta Pandit-Taskar, Alice C Fan, Phillip All |
|
| 2024-09-11 |
[Comment] Treatment of Richter transformation—immunotherapy to the rescue? |
Othman Al-Sawaf, Barbara Eichhorst |
|
| 2024-09-06 |
[Articles] Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study |
Laura A Dawson, Jolie Ringash, Alysa Fairchild, Paul Stos, Kristopher Dennis, Aamer Mahmud, Teri Lynn Stuckless, Francois Vincent, David Roberge, Matthew Follwell, Raimond K W Wong, Derek J Jonker, Jennifer J Knox, Camilla Zimmermann, Philip Wong, Aisling |
|
| 2024-09-06 |
[News] New developments in tobacco control measures in Europe |
Talha Burki |
|
| 2024-09-06 |
[News] European Commission approval for Dutch investment in radiopharmaceuticals |
Karl Gruber |
|
| 2024-09-02 |
[Comment] Radiation oncology: a call for papers for ESTRO 2025 |
David Collingridge, Pierre Blanchard |
|
| 2024-08-31 |
[News] World's first lung cancer vaccine trial launched in the UK |
Elizabeth Gourd |
|
| 2024-08-31 |
[News] Continued suboptimal HPV vaccine coverage in the USA |
Talha Burki |
|
| 2024-08-29 |
[Policy Review] Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE |
Philippe Morice, Giovanni Scambia, Nadeem R Abu-Rustum, Maribel Acien, Alessandro Arena, Sara Brucker, Ying Cheong, Pierre Collinet, Francesco Fanfani, Francesca Filippi, Ane Gerda Zahl Eriksson, Sebastien Gouy, Philipp Harter, Xavier Matias-Guiu, George |
|
| 2024-08-23 |
[News] Medicare drug price negotiations by the US Government |
Sharmila Devi |
|
| 2024-08-21 |
[Comment] The UK needs to be a leader, not a lagger, in the global cancer effort |
Mark Lawler, Ajay Aggarwal, Julie Gralow, Richard Sullivan, Pat Price |
|
| 2024-08-17 |
[Articles] Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis |
Yi Zhao, Ying He, Wei Wang, Qi Cai, Fan Ge, Zisheng Chen, Jianqi Zheng, Yuan Zhang, Hongsheng Deng, Ying Chen, Shen Lao, Hengrui Liang, Wenhua Liang, Jianxing He |
|
| 2024-08-17 |
[News] Peru advances towards universal health care for patients with cancer |
Talha Burki |
|
| 2024-08-17 |
[News] Progress in NCD screening in Mongolia |
Sharmila Devi |
|
| 2024-08-14 |
[Perspectives] Ending financial discrimination for cancer survivors: embedding the Right to be Forgotten in legislation across Europe |
Mark Lawler, Grazia Scocca, Françoise Meunier |
|
| 2024-08-13 |
[Articles] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial |
Emanuel Bührer, Michal Kicinski, Mario Mandala, Madeline Pe, Georgina V Long, Victoria Atkinson, Christian U Blank, Andrew Haydon, Stéphane Dalle, Adnan Khattak, Matteo S Carlino, Andrey Meshcheryakov, Shahneen Sandhu, Susana Puig, Dirk Schadendorf, Rahim |
|
| 2024-08-13 |
[Comment] Measuring success of adjuvant treatment for patients with melanoma |
Brent O'Carrigan, Pippa G Corrie |
|
| 2024-08-10 |
[Articles] Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phas |
Pierre Vera, Sébastien Thureau, Florence Le Tinier, Philippe Chaumet-Riffaud, Sébastien Hapdey, Hélène Kolesnikov-Gauthier, Etienne Martin, Alina Berriolo-Riedinger, Nicolas Pourel, Jean Marc Broglia, Pierre Boissellier, Sophie Guillemard, Naji Salem, Isa |
|
| 2024-08-09 |
[News] Disappointment facing patients with breast cancer as trastuzumab deruxtecan too expensive for NHS |
Elizabeth Gourd |
|
| 2024-08-08 |
[Articles] Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial |
Jean-Yves Blay, Quentin Devin, Florence Duffaud, Maud Toulmonde, Nelly Firmin, Olivier Collard, Emmanuelle Bompas, Benjamin Verret, Isabelle Ray-Coquard, Sebastien Salas, Clemence Henon, Charles Honoré, Mehdi Brahmi, Armelle Dufresne, Marc Pracht, Alice H |
|
| 2024-08-08 |
[Articles] Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial |
Linda J Williams, Ian H Kunkler, Karen J Taylor, Joanna Dunlop, Tammy Piper, Jacqueline Caldwell, Wilma Jack, Joseph F Loane, Kenneth Elder, John M S Bartlett, J Michael Dixon, David A Cameron |
|
| 2024-08-08 |
[Comment] Who does not benefit from whole-breast radiotherapy and how to find them? |
Hans-Christian Kolberg, Cornelia Kolberg-Liedtke |
|
| 2024-08-08 |
[Comment] Imatinib in advanced GIST: if it's working, don’t stop a good thing |
Ryan A Denu, Neeta Somaiah |
|
| 2024-08-08 |
[Articles] Cancer incidence and survival for 11 cancers in the Commonwealth: a simulation-based modelling study |
Zachary J Ward, Qassi Gaba, Rifat Atun |
|
| 2024-08-07 |
[Articles] Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial |
Jana de Boniface, Matilda Appelgren, Robert Szulkin, Sara Alkner, Yvette Andersson, Leif Bergkvist, Jan Frisell, Oreste Davide Gentilini, Michalis Kontos, Thorsten Kühn, Dan Lundstedt, Birgitte Vrou Offersen, Roger Olofsson Bagge, Toralf Reimer, Malin Sun |
|
| 2024-08-07 |
[Comment] Time to abandon axillary lymph node dissection in early-stage breast cancer |
Andrea V Barrio |
|
| 2024-08-06 |
[Articles] Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial |
Kanwal Raghav, Salvatore Siena, Atsuo Takashima, Takeshi Kato, Marc Van den Eynde, Filippo Pietrantonio, Yoshito Komatsu, Hisato Kawakami, Marc Peeters, Thierry Andre, Sara Lonardi, Kensei Yamaguchi, Jeanne Tie, Cristina Gravalos Castro, Hung-Chih Hsu, Jo |
|
| 2024-08-06 |
[Comment] Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more? |
Jeanine M L Roodhart, Miriam Koopman |
|
| 2024-08-03 |
[Articles] Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial |
Nicoletta Colombo, Elena Biagioli, Kenichi Harano, Francesca Galli, Emma Hudson, Yoland Antill, Chel Hun Choi, Manuela Rabaglio, Frederic Marmé, Christian Marth, Gabriella Parma, Lorena Fariñas-Madrid, Shin Nishio, Karen Allan, Yeh Chen Lee, Elisa Piovano |
|
| 2024-08-02 |
[News] New immigration laws could undermine cancer research in the UK |
Karl Gruber |
|
| 2024-08-02 |
[News] Poor progress on reducing alcohol consumption in Europe |
Talha Burki |
|
| 2024-07-30 |
[Articles] Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study |
Madeleine J Karpinski, Johannes Hüsing, Kevin Claassen, Lennart Möller, Hiltraud Kajüter, Florian Oesterling, Viktor Grünwald, Lale Umutlu, Jens Kleesiek, Tugce Telli, Anja Merkel-Jens, Anika Hüsing, Claudia Kesch, Ken Herrmann, Matthias Eiber, Sebastian |
|
| 2024-07-30 |
[Comment] Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer |
Kirsten Bouchelouche, Peter L Choyke |
|
| 2024-07-26 |
[News] Improving cancer control initiatives in Indigenous people |
Karl Gruber |
|
| 2024-07-26 |
[Comment] Molecular diagnosis and site-specific therapy in cancer of unknown primary: an important milestone |
F Anthony Greco, Chris Labaki, Elie Rassy |
|
| 2024-07-26 |
[Articles] Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial |
Xin Liu, Xiaowei Zhang, Shiyu Jiang, Miao Mo, Qifeng Wang, Yanli Wang, Liangping Zhou, Silong Hu, Huijuan Yang, Yifeng Hou, Yong Chen, Xueguan Lu, Yu Wang, Xiaoyan Zhou, Wentao Li, Cai Chang, Xiujiang Yang, Ke Chen, Jun Cao, Qinghua Xu, Yifeng Sun, Jianfe |
|
| 2024-07-26 |
[News] Over US$100 million pledged to improve cancer care across Africa |
Paul Adepoju |
|
| 2024-07-19 |
[News] Lifestyle factors driving cancer cases and mortality in the USA |
Karl Gruber |
|
| 2024-07-19 |
[News] Call for stricter tobacco control laws in Ghana |
Manjulika Das |
|
| 2024-07-19 |
[News] Impact of pharmacy benefit managers on cancer health care |
Priya Venkatesan |
|
| 2024-07-17 |
[Articles] Celiac plexus radiosurgery for pain management in advanced cancer: a multicentre, single-arm, phase 2 trial |
Yaacov R Lawrence, Marcin Miszczyk, Laura A Dawson, Dayssy Alexandra Diaz Pardo, Artur Aguiar, Dror Limon, Raphael M Pfeffer, Michael Buckstein, Aisling S Barry, Tikva Meron, Adam P Dicker, Jerzy Wydmański, Camilla Zimmermann, Ofer Margalit, David Hausner |
|
| 2024-07-17 |
[Comment] Alleviating retroperitoneal pain with celiac plexus radiosurgery |
Daniel Moore-Palhares, Sylvia S W Ng, Alexander V Louie |
|
| 2024-07-16 |
[Articles] Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study |
Guihong Wan, Wenxin Chen, Sara Khattab, Katie Roster, Nga Nguyen, Boshen Yan, Ahmad Rajeh, Jayhyun Seo, Hannah Rashdan, Leyre Zubiri, Matthew J Hadfield, Shadmehr Demehri, Kun-Hsing Yu, William Lotter, Alexander Gusev, Nicole R LeBoeuf, Kerry L Reynolds, |
|
| 2024-07-13 |
[News] Leaked documents suggest Philip Morris International's link to research activities |
Talha Burki |
|
| 2024-07-12 |
[Articles] Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis |
Kristina Jenei, Arianna Gentilini, Alyson Haslam, Vinay Prasad |
|
| 2024-07-09 |
[Policy Review] NHS cancer services and systems—ten pressure points a UK cancer control plan needs to address |
Ajay Aggarwal, Richard Simcock, Pat Price, Bernard Rachet, Georgios Lyratzopoulos, Kate Walker, Katie Spencer, Tom Roques, Richard Sullivan |
|
| 2024-07-06 |
[Articles] Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort study |
Dimitris Bertsimas, Georgios Antonios Margonis, Suleeporn Sujichantararat, Angelos Koulouras, Yu Ma, Cristina R Antonescu, Murray F Brennan, Javier Martín-Broto, Seehanah Tang, Piotr Rutkowski, Martin E Kreis, Katharina Beyer, Jane Wang, Elzbieta Bylina, |
|
| 2024-07-05 |
[News] Carcinogenicity of talc and acrylonitrile |
Leslie T Stayner, Tania Carreón-Valencia, Paul A Demers, Jason M Fritz, Malcolm R Sim, Patricia Stewart, Hiroyuki Tsuda, Andres Cardenas, Dario Consonni, Laurie Davies, Sara De Matteis, Emanuela Felley-Bosco, Andrew J Ghio, Thomas Göen, Yann Grosse, Aless |
|
| 2024-07-05 |
[News] Nigeria mandates reporting of all cancer diagnoses |
Paul Adepoju |
|
| 2024-07-05 |
[News] New report from STRONG-AYA on addressing needs of adolescents and young adults with cancer in Europe |
Manjulika Das |
|
| 2024-07-05 |
[News] ESMO Gastrointestinal Cancers Congress 2024 |
Katherine Gourd |
|
| 2024-07-02 |
[Articles] Premature mortality trends in 183 countries by cancer type, sex, WHO region, and World Bank income level in 2000–19: a retrospective, cross-sectional, population-based study |
Shilpa S Murthy, Dario Trapani, Bochen Cao, Freddie Bray, Shashanka Murthy, Thomas Peter Kingham, Chandrakanth Are, André M Ilbawi |
|
| 2024-07-02 |
[Comment] Cancer and premature mortality—pushing the frontiers of cancer care |
Andrew Toyin Olagunju |
|
| 2024-06-29 |
[Comment] ImmunoPET in high-grade neuroendocrine tumours |
Francesco Giammarile, Roberto C Delgado Bolton, Fuad Novruzov, Diana Paez |
|
| 2024-06-29 |
[Articles] Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial |
Salomon Tendler, Mark P Dunphy, Matthew Agee, Joseph O'Donoghue, Rania G Aly, Noura J Choudhury, Adam Kesner, Assen Kirov, Audrey Mauguen, Marina K Baine, Heiko Schoder, Wolfgang A Weber, Natasha Rekhtman, Serge K Lyashchenko, Lisa Bodei, Michael J Morris |
|
| 2024-06-28 |
[News] New Zealand expands cancer treatment with funding boost |
Paul Adepoju |
|
| 2024-06-27 |
[Articles] Risks of adverse obstetric outcomes among female survivors of adolescent and young adult cancer in England (TYACSS): a population-based, retrospective cohort study |
Ceren Sunguc, David L Winter, Emma J Heymer, Gavin Rudge, Angela Polanco, Katherine A Birchenall, Melanie Griffin, Richard A Anderson, W Hamish B Wallace, Michael M Hawkins, Raoul C Reulen |
|
| 2024-06-27 |
[Comment] Closing the research gaps in obstetric health for survivors of cancer |
Ranjeet Bajpai, Jyoti Bajpai |
|
| 2024-06-26 |
[Articles] Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study |
Mohamad E Allaf, Se-Eun Kim, Viraj Master, David F McDermott, Lauren C Harshman, Suzanne M Cole, Charles G Drake, Sabina Signoretti, Mahmut Akgul, Nicholas Baniak, Elsa Li-Ning, Matthew B Palmer, Hamid Emamekhoo, Nabil Adra, Hristos Kaimakliotis, Yasser G |
|
| 2024-06-26 |
[Comment] Perioperative immunotherapy in renal cell carcinoma |
Delphine Borchiellini, Karim Bensalah |
|
| 2024-06-21 |
[News] Cancer priorities set out in manifestos as organisations warn of worsening standards |
Emma Wilkinson |
|
| 2024-06-15 |
[Articles] Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled p |
Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Sonja Zweegman, Hélène Caillon, Denis Caillot, Hervé Avet-Loiseau, Michel Delforge, Thomas Dejoie, Thierry Facon, Cécile Sonntag, Jean Fontan, Mohamad Mohty, |
|
| 2024-06-15 |
[Comment] Daratumumab maintenance in patients with myeloma |
Meral Beksac |
|
| 2024-06-14 |
[News] Four industries responsible for millions of deaths each year |
Talha Burki |
|
| 2024-06-12 |
[Articles] Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study |
Anindo Saha, Joeran S Bosma, Jasper J Twilt, Bram van Ginneken, Anders Bjartell, Anwar R Padhani, David Bonekamp, Geert Villeirs, Georg Salomon, Gianluca Giannarini, Jayashree Kalpathy-Cramer, Jelle Barentsz, Klaus H Maier-Hein, Mirabela Rusu, Olivier Rou |
|
| 2024-06-12 |
[Comment] Artificial intelligence for scoring prostate MRI: ready for prospective evaluation |
Martin Eklund |
|
| 2024-06-07 |
[Articles] Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study |
Jie-Hai Yu, Bin-Yi Xiao, Dan-Dan Li, Wu Jiang, Ya Ding, Xiao-Jun Wu, Rong-Xin Zhang, Jun-Zhong Lin, Wei Wang, Kai Han, Ling-Heng Kong, Xin-Ke Zhang, Bi-Yun Chen, Wei-Jian Mei, Zhi-Zhong Pan, Jing-Hua Tang, Xiao-Shi Zhang, Pei-Rong Ding |
|
| 2024-06-07 |
[News] UK NHS to enrol thousands in trials of personalised mRNA cancer vaccines |
Tony Kirby |
|
| 2024-06-07 |
[News] New Canadian draft breast screening guidelines issued |
Renée Pellerin |
|
| 2024-06-07 |
[News] Cancer updates from the 77th World Health Assembly |
Paul Adepoju |
|
| 2024-06-06 |
[Articles] Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial |
Douglas Adkins, Jessica C Ley, Jingxia Liu, Peter Oppelt |
|
| 2024-06-05 |
[Articles] Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised |
Joachim G Aerts, Robert Belderbos, Paul Baas, Arnaud Scherpereel, Koen Bezemer, Ilona Enninga, Rob Meijer, Marcella Willemsen, Rossana Berardi, Dean Fennell, Rene Kerstens, Robin Cornelissen, Jan P van Meerbeeck, DENIM team |
|
| 2024-06-05 |
[Comment] Refreshing the mesothelioma catalogue: tailoring cellular therapy in the DENIM trial |
Marjorie G Zauderer, Ibiayi Dagogo-Jack |
|
| 2024-06-04 |
[Personal View] A manifesto for improving cancer detection: four key considerations when implementing innovations across the interface of primary and secondary care |
Anna Dowrick, Sue Ziebland, Tanvi Rai, Claire Friedemann Smith, Brian D Nicholson |
|
| 2024-06-02 |
[Articles] Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study |
Jean-Luc Van Laethem, Ivan Borbath, Hans Prenen, Karen Paula Geboes, Aurélien Lambert, Emmanuel Mitry, Philippe Alexandre Cassier, Jean-Frédéric Blanc, Lorenzo Pilla, Jaime Feliu Batlle, Mercedes Rodriguez Garrote, Roberto Antonio Pazo-Cid, Inmaculada Gal |
|
| 2024-06-02 |
[Comment] Small steps can lead to substantial breakthroughs: moving the therapeutic needle forward in pancreatic cancer |
Priyadarshini Pathak, Colin Weekes, Jennifer Y Wo |
|
| 2024-06-01 |
[News] Tobacco and e-cigarette use in young people: an ongoing challenge |
Talha Burki |
|
| 2024-05-31 |
[Comment] Can a Major Conditions Strategy substitute for a National Cancer Control Plan? |
Ajay Aggarwal, Richard Sullivan |
|
| 2024-05-30 |
[Articles] BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study |
Yuxiang Ma, Yan Huang, Yuanyuan Zhao, Shen Zhao, Jinhui Xue, Yunpeng Yang, Wenfeng Fang, Ye Guo, Yaqian Han, Kunyu Yang, Yongsheng Li, Jun Yang, Zhenming Fu, Gang Chen, Likun Chen, Ningning Zhou, Ting Zhou, Yaxiong Zhang, Huaqiang Zhou, Qianwen Liu, Yi Zh |
|
| 2024-05-30 |
[Correction] Correction to Lancet Oncol 2024; 25: 833 |
|
|
| 2024-05-29 |
[Policy Review] Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Work |
Yi Lin, Lugui Qiu, Saad Usmani, Chng Wee Joo, Luciano Costa, Benjamin Derman, Juan Du, Hermann Einsele, Carlos Fernandez de Larrea, Roman Hajek, P Joy Ho, Efstathios Kastritis, Joaquin Martinez-Lopez, Maria-Victoria Mateos, Joseph Mikhael, Philippe Moreau |
|
| 2024-05-24 |
[News] Kenya sounds alarm over counterfeit cancer drugs |
Paul Adepoju |
|
| 2024-05-24 |
[News] Call for actions to address hepatocellular carcinoma in sub-Saharan Africa |
Paul Adepoju |
|
| 2024-05-17 |
[News] Medical debt of people with cancer in the USA |
Talha Burki |
|
| 2024-05-14 |
[Articles] Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis |
Huseyin Naci, Yichen Zhang, Steven Woloshin, Xiaodong Guan, Ziyue Xu, Anita K Wagner |
|
| 2024-05-14 |
[Articles] Effect of Project Orbis participation by the Swiss regulator on submission gaps, review times, and drug approval decisions between 2020 and 2022: a comparative analysis |
Matea Zosso-Pavic, Qiyu Li, Eiman Atiek, Anita Wolfer, Ulrich-Peter Rohr |
|
| 2024-05-14 |
[Comment] Global cooperation and early access—clinical outcomes matter |
Ariadna Tibau, Aaron S Kesselheim |
|
| 2024-05-11 |
[News] ESTRO 2024 |
David Collingridge |
|
| 2024-05-11 |
[Articles] Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial |
Andrea Necchi, Mathieu Roumiguié, Ashish M Kamat, Neal D Shore, Joost L Boormans, Ahmet Adil Esen, Thierry Lebret, Shuya Kandori, Dean F Bajorin, Laurence E M Krieger, Scot A Niglio, Edward M Uchio, Ho Kyung Seo, Ronald de Wit, Eric A Singer, Petros Griva |
|
| 2024-05-11 |
[News] Protests in South Africa over unused cancer-treatment fund |
Paul Adepoju |
|
| 2024-05-11 |
[News] Cancer on the agenda during IAEA Director General's visit to Chile |
Manjulika Das |
|
| 2024-05-04 |
[Articles] Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study |
Bob T Li, Funda Meric-Bernstam, Aditya Bardia, Yoichi Naito, Salvatore Siena, Philippe Aftimos, Ian Anderson, Giuseppe Curigliano, Maria de Miguel, Maitri Kalra, Do-Youn Oh, Joon Oh Park, Sophie Postel-Vinay, Sun Young Rha, Taroh Satoh, Iben Spanggaard, F |
|
